rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    PLRX
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2026 Financial Results

      FORTIFY, a Phase 1b indication expansion trial of PLN-101095, continues strong enrollment Pliant’s proprietary selective, targeted, integrin-mediated delivery platform demonstrates encouraging initial preclinical results Strengthened leadership team with appointments of David Raben, M.D., as Chief Medical Officer and Craig Blanchette, Ph.D., as Senior Vice President, Research (RNAi) SOUTH SAN FRANCISCO, Calif., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinica

      Nov 12Yahoo FinancePLRX
      Pliant Therapeutics Announces Presentation of PLN-101095 Preclinical and Clinical Data at the 2026 Annual Meeting of the Society for Immunotherapy of Cancer
      Nov 9Yahoo FinancePLRX
      Pliant Therapeutics Announces Presentations at the 2026 Annual Meeting of the Society for Immunotherapy of Cancer

      SOUTH SAN FRANCISCO, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company focused on the discovery and development of integrin-based therapeutics, today announced two presentations related to PLN-101095 at the upcoming 41st Annual Meeting of the Society for Immunotherapy of Cancer (SITC) taking place November 4 - 8, 2026 at the Phoenix Convention Center in Phoenix, Arizona. Poster Presentations Title: Selective targeting of in

      Oct 29Yahoo FinancePLRX
      Pliant Therapeutics appoints Craig Blanchette as SVP, Research
      Oct 20Investing.comPLRX
      Pliant Therapeutics Announces Upcoming Presentation at European Society for Medical Oncology Congress 2026
      Oct 19Yahoo FinancePLRX
      Pliant Therapeutics names David Raben as chief medical officer
      Sep 30Investing.comPLRX
      Pliant Therapeutics Appoints David Raben, M.D., as Chief Medical Officer

      Leader in targeted immuno-oncology drug development brings three decades of academic and biopharmaceutical oncology expertiseSOUTH SAN FRANCISCO, ...

      Sep 30Business InsiderPLRX
      Pliant Therapeutics Appoints David Raben as Chief Medical Officer
      Sep 30Yahoo FinancePLRX

      This is the newest page. Registered accounts read further back.